Search

Introduction: To address cardiovascular (CV) complications and their relationship to clinical outcomes in hospitalized patients with COVID-19. Methods: A total of 196 hospitalized patients with COVID-19 were enrolled in this retrospective single-center cohort study from September 10, 2020, to December 10, 2020, with a median age of 65 years (IQR, 52-77). Follow-up continued for 3 months after hospital discharge. Results: CV complication was observed in 54 (27.6%) patients, with arrhythmia being the most prevalent (14.8%) followed by myocarditis, acute coronary syndromes, ST-elevation myocardial infarction, cerebrovascular accident, and deep vein thrombosis in 15 (7.7%), 12 (6.1%), 10 (5.1%), 8 (4.1%), and 4 (2%) patients, respectively. The proportion of patients with elevated high-sensitivity troponin I, N-terminal pro-B-type natriuretic peptide, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction was greater in the CV complication group. Severe forms of COVID-19 comprised nearly two-thirds (64.3%) of our study population and constituted a significantly higher share of the CV complication group members (75.9% vs 59.9%; P = 0.036). Intensive care unit admission (64.8% vs 44.4%; P = 0.011) and stay (5.5 days vs 0 day; P = 0.032) were notably higher in patients with CV complications. Among 196 patients, 50 died during hospitalization and 10 died after discharge, yielding all-cause mortality of 30.8%. However, there were no between-group differences concerning mortality. Age, heart failure, cancer/autoimmune disease, disease severity, interferon beta-1a, and arrhythmia were the independent predictors of all-cause mortality during and after hospitalization. Conclusion: CV complications occurred widely among COVID-19 patients. Moreover, arrhythmia, as the most common complication, was associated with increased mortality. [ABSTRACT FROM AUTHOR]

Objective: This study was conducted to investigate the effect of contrast agent used in angiography on sensorineural hearing loss. Methodology: This Quasi experimental study was conducted at Valiasr hospital, Birjand, Iran on 157 coronary artery disease patients hospitalized for angiography. The hearing level of the right and left ears was measured individually before and after the angiography. Then, to calculate the mean auditory threshold of the patients, the hearing level was averaged at three different frequencies of 500, 1000, and 2000 Hz. After data collection and introducing them into SPSS 22, descriptive statistics (frequency percentage distribution, mean and standard deviation) were used along with Mann-Whitney and Kruskal-Wallis tests at the significance level of 0.05. Results: Out of the 157 patients studied, 79 (50.3%) were male. The mean age of the subjects was 57.62±10.17 years (29-85 years), which was 57.67±9.31 in women and 56.85±11 in men. The hearing level of the right ear before and after injection of the radiocontrast agent was 23.69±13.18 and 23.33±13.30 db, respectively, while in the left ear, the values were 25.14±15.01 and 25.02±15.16, respectively, where this difference was not significant (p>0.05). Conclusion: There is no appreciable effect of radiocontrast agent on neurosensory auditory disorder of patients undergoing angiography of coronary artery disease [ABSTRACT FROM AUTHOR]